Home › Companies › Neurocrine Biosciences, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Neurocrine Biosciences, Inc.’s Form 8-K, filed 2026-05-28 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Neurocrine Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Neurocrine Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Kevin C. Gorman, Ph.D. | 76,228,063 | -- | -- | 8,538,217 | 5,352,345 | Majority: yes |
| Elect Director: Gary A. Lyons | 75,278,705 | -- | -- | 9,487,575 | 5,352,345 | Majority: yes |
| Elect Director: Johanna Mercier | 74,671,942 | -- | -- | 10,094,338 | 5,352,345 | Majority: yes |
| The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2025 Plan. | 79,131,622 | 5,568,926 | 65,732 | -- | 5,352,345 | Majority: yes |
| The Amended 2025 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. | 83,880,185 | 6,170,483 | 67,957 | -- | -- | Majority: yes |
Source: Neurocrine Biosciences, Inc., Form 8-K, filed with the SEC on 2026-05-28 — read the filing on EDGAR.
Each item below shows how the 637 asset managers that disclosed a Neurocrine Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Neurocrine Biosciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-05-27.
Combines 16 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Neurocrine Biosciences, Inc.’s own tally for this item (“The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2025 Plan.”): 79,131,622 for, 5,568,926 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 79% for, 6% against (84% of the company cast a for/against vote).
The 631 asset managers below cast 95% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,318,584 | 0 | 0 | 0 | For |
| Vanguard | 11,660,541 | 9 | 0 | 0 | For |
| Dodge & Cox | 9,613,226 | 0 | 0 | 0 | For |
| State Street | 3,910,807 | 3,514 | 0 | 0 | For |
| JPMorgan | 3,419,737 | 0 | 0 | 0 | For |
| AQR | 3,206,054 | 0 | 0 | 0 | For |
| Fidelity | 2,184,284 | 6,440 | 0 | 0 | For |
| Two Sigma | 2,133,902 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,121,019 | 0 | 0 | 0 | For |
| Victory Capital | 2,003,607 | 0 | 0 | 0 | For |
| Charles Schwab | 1,824,190 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,400,528 | 0 | 0 | Against |
| Northern Trust | 1,173,346 | 0 | 0 | 0 | For |
| Wellington | 1,133,580 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 1,062,072 | 0 | 0 | 0 | For |
| Renaissance | 1,048,779 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 983,720 | 0 | 0 | 0 | For |
| First Trust | 956,712 | 0 | 0 | 0 | For |
| Janus Henderson | 916,051 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 739,730 | 0 | 0 | 0 | For |
| Invesco | 0 | 581,687 | 0 | 0 | Against |
| Swedbank Robur Fonder AB | 0 | 567,629 | 0 | 0 | Against |
| GW&K Investment Management, LLC | 559,141 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 493,040 | 0 | 0 | 0 | For |
Showing the 25 largest of 631 asset managers. See all 631 in the interactive database.
Meeting held 2026-05-27.
Combines 5 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Neurocrine Biosciences, Inc.’s own tally for this item (“The Amended 2025 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 83,880,185 for, 6,170,483 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 83% for, 6% against (90% of the company cast a for/against vote).
The 144 asset managers below cast 99.6% of the shares they voted on this item FOR (40,072,186 for, 150,201 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,879,594 | 5,801 | 0 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 2,036,275 | 0 | 0 | 0 | For |
| State Street | 1,372,187 | 69 | 0 | 0 | For |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 950,339 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 230,456 | 0 | 0 | 0 | For |
| Equitable | 223,829 | 0 | 0 | 0 | For |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 204,682 | 0 | 0 | 0 | For |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 178,551 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 169,230 | 0 | 0 | 0 | For |
| Northwestern Mutual | 148,519 | 0 | 0 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 144 asset managers. See all 144 in the interactive database.
Meeting held 2026-05-27.
Combines 4 wordings of this item as funds reported it.
98% fund support · no official result
The 142 asset managers below cast 98% of the shares they voted on this item FOR (39,122,593 for, 975,913 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,874,703 | 10,691 | 0 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 1,790,435 | 245,840 | 0 | 0 | For |
| State Street | 1,370,066 | 2,190 | 0 | 0 | For |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 950,339 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 230,456 | 0 | 0 | 0 | For |
| Equitable | 223,829 | 0 | 0 | 0 | For |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 204,682 | 0 | 0 | 0 | For |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 178,551 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 0 | 169,230 | 0 | 0 | Against |
| Northwestern Mutual | 148,519 | 0 | 0 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.
Meeting held 2026-05-27.
Combines 11 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Neurocrine Biosciences, Inc.’s own tally for this item (“Elect Director: Gary A. Lyons”): 75,278,705 for, 9,487,575 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 75% for, 9% withheld (84% of the company cast a for/withheld vote).
The 140 asset managers below cast 100% of the shares they voted on this item FOR (38,066,712 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,885,373 | 0 | 22 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 2,036,275 | 0 | 0 | 0 | For |
| State Street | 4,869 | 0 | 1,367,387 | 0 | Abstain |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 950,339 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 230,456 | 0 | Abstain |
| Equitable | 34,452 | 0 | 189,377 | 0 | Abstain |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 204,682 | 0 | Abstain |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 178,551 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 169,230 | 0 | 0 | 0 | For |
| Northwestern Mutual | 148,519 | 0 | 0 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.
Meeting held 2026-05-27.
Combines 11 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Neurocrine Biosciences, Inc.’s own tally for this item (“Elect Director: Johanna Mercier”): 74,671,942 for, 10,094,338 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 74% for, 10% withheld (84% of the company cast a for/withheld vote).
The 140 asset managers below cast 100% of the shares they voted on this item FOR (38,099,627 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,879,585 | 0 | 5,810 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 2,036,275 | 0 | 0 | 0 | For |
| State Street | 4,938 | 0 | 1,367,318 | 0 | Abstain |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 950,339 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 230,456 | 0 | 0 | 0 | For |
| Equitable | 34,452 | 0 | 189,377 | 0 | Abstain |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 204,682 | 0 | Abstain |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 178,551 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 169,230 | 0 | 0 | 0 | For |
| Northwestern Mutual | 101,844 | 0 | 46,675 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.
Meeting held 2026-05-27.
Combines 12 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Neurocrine Biosciences, Inc.’s own tally for this item (“Elect Director: Kevin C. Gorman, Ph.D.”): 76,228,063 for, 8,538,217 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 76% for, 8% withheld (84% of the company cast a for/withheld vote).
The 140 asset managers below cast 100% of the shares they voted on this item FOR (38,066,713 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,885,374 | 0 | 21 | 0 | For |
| BlackRock | 7,355,109 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,419,163 | 0 | 0 | 0 | For |
| JPMorgan | 3,365,627 | 0 | 0 | 0 | For |
| Fidelity | 2,036,275 | 0 | 0 | 0 | For |
| State Street | 4,869 | 0 | 1,367,387 | 0 | Abstain |
| Victory Capital | 1,303,471 | 0 | 0 | 0 | For |
| First Trust | 950,339 | 0 | 0 | 0 | For |
| Charles Schwab | 887,595 | 0 | 0 | 0 | For |
| Jackson National | 510,881 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 435,679 | 0 | 0 | 0 | For |
| AQR | 433,505 | 0 | 0 | 0 | For |
| TIAA | 416,263 | 0 | 0 | 0 | For |
| Dimensional | 265,368 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 230,456 | 0 | Abstain |
| Equitable | 34,452 | 0 | 189,377 | 0 | Abstain |
| Invesco | 220,128 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 217,899 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 204,682 | 0 | Abstain |
| Allspring | 180,991 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 178,551 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 169,230 | 0 | 0 | 0 | For |
| Northwestern Mutual | 148,519 | 0 | 0 | 0 | For |
| Eaton Vance | 144,270 | 0 | 0 | 0 | For |
| Prudential/PGIM | 142,115 | 0 | 0 | 0 | For |
Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.
Meeting held 2025-05-21 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
Combines 3 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Neurocrine Biosciences, Inc.’s own tally for this item (“The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the 2025 Plan.”): 72,648,862 for, 12,884,104 against, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 100,600,000 outstanding shares: 72% for, 13% against (85% of the company cast a for/against vote).
The 4 asset managers below cast 98% of the shares they voted on this item FOR (131,214 for, 2,989 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GLENMEDE FUND INC | 126,124 | 0 | 0 | 0 | For |
| Investment Management Corp of Ontario | 4,990 | 0 | 0 | 0 | For |
| OSSIAM | 0 | 2,989 | 0 | 0 | Against |
| OSBORNE PARTNERS CAPITAL MANAGEMENT, LLC | 100 | 0 | 0 | 0 | For |
Meeting held 2026-05-27.
92% fund support · no official result
The 3 asset managers below cast 92% of the shares they voted on this item FOR (68,835 for, 5,720 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 46,735 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 22,100 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 5,720 | 0 | 0 | Against |
Meeting held 2026-05-27.
100% fund support · no official result
The 3 asset managers below cast 100% of the shares they voted on this item FOR (46,558 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Cardano Risk Management B.V. | 36,916 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 6,500 | 0 | 0 | 0 | For |
| Union Investment Management GmbH | 3,142 | 0 | 0 | 0 | For |
Meeting held 2026-05-27.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (49,755 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| HUSSMAN INVESTMENT TRUST | 40,000 | 0 | 0 | 0 | For |
| THOMPSON IM FUNDS INC | 9,755 | 0 | 0 | 0 | For |
Ranked by the number of Neurocrine Biosciences, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 100,600,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 12.25% |
| 2 | Vanguard | 11.59% |
| 3 | Dodge & Cox | 9.56% |
| 4 | State Street | 3.89% |
| 5 | JPMorgan | 3.41% |
| 6 | AQR | 3.19% |
| 7 | Fidelity | 2.18% |
| 8 | Two Sigma | 2.12% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.11% |
| 10 | Victory Capital | 1.99% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 13.31% | 13F |
| The Vanguard Group | 10.07% | DEF14A |
| Dodge & Cox | 5.50% | DEF14A |
| JPMorgan Chase | 5.41% | 13F |
| State Street | 4.33% | 13F |
| Two Sigma | 3.04% | 13F |
| Renaissance Technologies | 2.40% | 13F |
| Kevin C. Gorman, Ph.D. | 1.56% | DEF14A |
| Wellington Management | 1.38% | 13F |
| Kyle W. Gano, Ph.D. | 0.63% | DEF14A |
Percentages above are of 100,600,000 shares outstanding, as reported by Neurocrine Biosciences, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Neurocrine Biosciences, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Neurocrine Biosciences, Inc.'s shareholder meeting held 2026-05-27, in the 2025-2026 proxy season, 637 asset managers reported how they voted in their SEC Form N-PX filings, covering 4,732 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote on the compensation paid to the Company's named executive officers; — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Neurocrine Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-28.
Neurocrine Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).